Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Resource Type
Academic Journal
Authors
Garcia JS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Flamand Y; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.; Penter L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Keng M; Division of Hematology/Oncology, University of Virginia, Charlottesville, VA.; Tomlinson BK; Department of Hematology/Oncology, Case Comprehensive Cancer Center, Cleveland, OH.; Mendez LM; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA.; Koller P; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.; Cullen N; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.; Arihara Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Pfaff K; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.; Wolff JO; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.; Brunner AM; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Galinsky I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Bashey A; The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA.; Antin JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cutler C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Ho V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Jonas BA; Division of Cellular Therapy, BMT and Malignant Hematology, University of California, Davis, Sacramento, CA.; Luskin MR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Wadleigh M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Winer ES; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Savell A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Leonard R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Robertson T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Streicher H; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.; Rodig SJ; Department of Pathology, Brigham and Women's Hospital, Boston, MA.; Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; DeAngelo DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Neuberg D; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.; Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Soiffer RJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Source
Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE